

Rosalind J Walley

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4784609/publications.pdf>

Version: 2024-02-01

16
papers

1,286
citations

933264

10
h-index

996849

15
g-index

17
all docs

17
docs citations

17
times ranked

1940
citing authors

#	ARTICLE	IF	CITATIONS
1	Pharmaco-metabonomic phenotyping and personalized drug treatment. <i>Nature</i> , 2006, 440, 1073-1077.	13.7	787
2	Statistical evaluation of biomarkers as surrogate endpoints: a literature review. <i>Statistics in Medicine</i> , 2006, 25, 183-203.	0.8	150
3	Minimizing Patient Burden Through the Use of Historical Subject-Level Data in Innovative Confirmatory Clinical Trials: Review of Methods and Opportunities. <i>Therapeutic Innovation and Regulatory Science</i> , 2018, 52, 546-559.	0.8	78
4	Phosphodiesterase Type 5 Inhibition Reduces Albuminuria in Subjects with Overt Diabetic Nephropathy. <i>Journal of the American Society of Nephrology: JASN</i> , 2016, 27, 3459-3468.	3.0	52
5	Gas chromatography/flare ionisation detection mass spectrometry for the detection of endogenous urine metabolites for metabonomic studies and its use as a complementary tool to nuclear magnetic resonance spectroscopy. <i>Rapid Communications in Mass Spectrometry</i> , 2006, 20, 2271-2280.	0.7	44
6	Advantages of a wholly Bayesian approach to assessing efficacy in early drug development: a case study. <i>Pharmaceutical Statistics</i> , 2015, 14, 205-215.	0.7	41
7	The translational challenge in the development of new and effective therapies for endometriosis: a review of confidence from published preclinical efficacy studies. <i>Human Reproduction Update</i> , 2011, 17, 791-802.	5.2	32
8	Designing Compound Subsets: Comparison of Random and Rational Approaches Using Statistical Simulation. <i>Journal of Chemical Information and Modeling</i> , 2007, 47, 2149-2158.	2.5	18
9	Addressing potential prior data conflict when using informative priors in proof-of-concept studies. <i>Pharmaceutical Statistics</i> , 2016, 15, 28-36.	0.7	18
10	Reducing Patient Burden in Clinical Trials Through the Use of Historical Controls: Appropriate Selection of Historical Data to Minimize Risk of Bias. <i>Therapeutic Innovation and Regulatory Science</i> , 2020, 54, 850-860.	0.8	15
11	Using Bayesian analysis in repeated preclinical <i>in vivo</i> studies for a more effective use of animals. <i>Pharmaceutical Statistics</i> , 2016, 15, 277-285.	0.7	14
12	Real-World Evidence Utilization in Clinical Development Reflected by US Product Labeling: Statistical Review. <i>Therapeutic Innovation and Regulatory Science</i> , 2020, 54, 1436-1443.	0.8	14
13	Pooling Different Safety Data Sources: Impact of Combining Solicited and Spontaneous Reports on Signal Detection In Pharmacovigilance. <i>Drug Safety</i> , 2019, 42, 1191-1198.	1.4	10
14	Bayesian Variable Selection for Fractional Factorial Experiments with Multilevel Categorical Factors. <i>Journal of Quality Technology</i> , 2009, 41, 228-240.	1.8	6
15	Optimising the tradeoff between type I and type II error rates in the Bayesian context. <i>Pharmaceutical Statistics</i> , 2021, 20, 710-720.	0.7	6
16	From innovative thinking to pharmaceutical industry implementation: Some success stories. <i>Pharmaceutical Statistics</i> , 2022, 21, 712-719.	0.7	1